This site is intended only for healthcare professionals residing in Malaysia

Search

Menu

Close

Log Out Our medicinesTherapy AreaExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer Medical Information

Menu

Close

HomeAbout DosingEfficacySafety and tolerabilityImportant safety information InteractionsFertility, Pregnancy and lactationUndesirable effectsGuidelinesResourcesProduct InformationEventsMaterialsVideos
Safety and tolerability InteractionsInteraction with other medicinal products and other forms of interactionNon-depolarising muscle relaxants

Piperacillin when used concomitantly with vecuronium has been implicated in the prolongation of the neuromuscular blockade of vecuronium. Due to their similar mechanisms of action, it is expected that the neuromuscular blockade produced by any of the non-depolarising muscle relaxants could be prolonged in the presence of piperacillin.

Anticoagulants

During simultaneous administration of heparin, oral anticoagulants and other drugs that may affect the blood coagulation system including thrombocyte function, appropriate coagulation tests should be performed more frequently and monitored regularly.

Methotrexate

Piperacillin may reduce the excretion of methotrexate; therefore, serum levels of methotrexate should be monitored in patients to avoid substance toxicity.

Probenecid

As with other penicillins, concurrent administration of probenecid and piperacillin/tazobactam produces a longer half-life and lower renal clearance for both piperacillin and tazobactam; however, peak plasma concentrations of either substances are unaffected.

Aminoglycosides

Piperacillin, either alone or with tazobactam, did not significantly alter the pharmacokinetics of tobramycin in subjects with normal renal function and with mild or moderate renal impairment. The pharmacokinetics of piperacillin, tazobactam, and the M1 metabolite were also not significantly altered by tobramycin administration.
 

Vancomycin

No pharmacokinetic interactions have been noted between piperacillin/tazobactam and vancomycin.

Effects on laboratory tests

Administration of Tazocin may result in a false-positive reaction for glucose in urine using a copper-reduction method. It is thus recommended that glucose tests based on enzymatic glucose oxidase reactions be used.

The direct Coombs test may be positive.

Bio-Rad Laboratories Platelia Aspergillus enzyme immunoassay (EIA) tests may lead to false-positive results for patients receiving Tazocin. Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with Bio‑Rad Laboratories Platelia Aspergillus EIA test have been reported.

Positive test results for the assays listed above in patients receiving Tazocin should be confirmed by other diagnostic methods.

Explore more safety and tolerability information Important safety information Learn more Loading Fertility, pregnancy and lactation Learn more Loading

No pharmacokinetic interactions have been noted between piperacillin/tazobactam and vancomycin.

No pharmacokinetic interactions have been noted between piperacillin/tazobactam and vancomycin.

Reference:Pfizer Malaysia Tazocin® EF Prescribing Information. Available at: https://labeling.pfizer.com/ShowLabeling.aspx?id=17746. Accessed on 15 July 2024.
More safety and tolerability contentGuidelines Learn moreLoading Product Information View Product Information Loading
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for healthcare professionals residing in Malaysia. If you are a member of public wishing to access information on a specific medicine, please consult with your doctor.

 

This website is brought to you by
Pfizer (Malaysia) Sdn Bhd 197801003134
(40131-T)
Level 10 & 11, Wisma Averis (Tower 2),
Bangsar South, No. 8, Jalan Kerinchi, 
59200 Kuala Lumpur, Malaysia.
Tel: 603-2281 6000 
Fax: 603-2281 6388 
 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

PP-TAZ-MYS-0132-24JUL2024
You are now leaving the PfizerPro Malaysia website
You are now being directed to a third-party website. It is clarified that Pfizer will not be collecting, storing, or accessing any personal information shared by you on the third-party website and Pfizer's Privacy Policy will not apply. Pfizer does not review or control or endorse the content of the third-party website and shall have no liability / assumes no responsibility for any issues arising out of you accessing the third-party website, accuracy of the information, practices, and standards of the third-party website. You will be bound by the Privacy Policy and Terms of Use of the third-party website and be solely responsible for your interactions with that website.
 
     PP-UNP-MYS-0077 - 10FEB2023